Neurology & CNS Deal Benchmarks
Deal benchmarks for Alzheimer's, Parkinson's, epilepsy, migraine, schizophrenia, and other neurological disorders. Benchmarks derived from 124 verified transactions.
124
Total Deals
$1.6B
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
35
license
32
acquisition
22
collaboration
20
option
8
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Nxera Pharma → Boehringer Ingelheim HTL-0048149 (GPR52 agonists) | option | $27M | $825M | Jun 2026 |
Centessa Pharmaceuticals → Eli Lilly cleminorexant | acquisition | $6.3B | $6.3B | Jun 2026 |
Ascidian Therapeutics → Eli Lilly and Company RNA exon-editing candidates | collaboration | $42M | $1.9B | Jun 2026 |
Avadel Pharmaceuticals → Alkermes Avadel narcolepsy/sleep medicine franchise | acquisition | $2.1B | $2.1B | Jun 2026 |
AriBio → Fosun Pharma phase 3 Alzheimer's candidate | option | $60M | — | May 2026 |
Neurona Therapeutics → UCB NRTX-1001 | acquisition | $650M | $1.1B | Apr 2026 |
Haisco Pharmaceutical Group → AbbVie HSK55718 and HSK51155 | license | $30M | $745M | Apr 2026 |
AC Immune → Lilly Alzheimer's collaboration | collaboration | $13M | — | Apr 2026 |
AC Immune SA → Eli Lilly and Company Morphomer Tau | license | $10M | $1.7B | Apr 2026 |
Centessa Pharmaceuticals → Eli Lilly Cleminorexton (ORX750) — full company acquisition | acquisition | $6.3B | $7.8B | Mar 2026 |
Benchmark Your Neurology & CNS Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 124 verified neurology & cns transactions.
Run Neurology & CNS Benchmark